Keep up with the latest developments from Clarus.

Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies
September 16, 2021
Clarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2021
Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies
September 9, 2021
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
July 15, 2021
Clarus Therapeutics Defeats Lipocine’s Patent Infringement Lawsuit on Summary Judgment
May 25, 2021
Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer
May 25, 2021
Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming a Publicly Listed Company to Address Unmet Needs of Men and Women Through Development of Androgen and Metabolic Therapies
April 27, 2021
Clarus Therapeutics Presents Positive Safety and Efficacy Data for Jatenzo® (testosterone undecanoate) Oral Capsules, CIII at ENDO 2021, the Endocrine Society's Annual Meeting
March 20, 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
February 24, 2021
Clarus Announces JATENZO® (testosterone undecanoate) Capsules, CIII now Covered by Express Scripts
December 7, 2020
Clarus Therapeutics Announces Financing to Support the Commercial Launch and Availability of JATENZO® (testosterone undecanoate) Capsules, CIII for the Treatment of Hypogonadism
March 16, 2020
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) Capsules, CIII for the Treatment of Hypogonadism
February 10, 2020
Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO® (testosterone undecanoate) Capsules CIII
December 11, 2019
Lipocine Withdraws Preliminary Injunction Threat Against Marketing of Clarus Therapeutics' JATENZO® Product: Trial Date Set for August 2020
August 26, 2019
Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo®
August 19, 2019
Clarus Therapeutics Refutes Patent Infringement Complaint
April 3, 2019
Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men
March 27, 2019

Upcoming Events

There are no events

Past Events

AUA 2021

Las Vegas, NV

September 10, 2021 – September 13, 2021

AACE 2021

Virtual

May 26, 2021 – May 29, 2021

ENDO 2021

San Diego, CA

March 20, 2021 – March 23, 2021

Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA)

Virtual

November 9, 2020 – November 15, 2020

Western Section of the AUA Annual Meeting

Virtual

October 25, 2020 – October 30, 2020

North Central Section of the AUA Annual Meeting

Virtual

October 15, 2020 – October 16, 2020

Southcentral Section of the AUA Annual Meeting

Virtual

October 10, 2020

American Society for Men’s Health

Virtual

October 3, 2020

Northeastern Section of the AUA Annual Meeting

Virtual

October 1, 2020 – October 3, 2020

New England Section of the AUA Annual Meeting

Virtual

September 10, 2020 – September 12, 2020

AUA Live

Virtual

June 27, 2020 – June 28, 2020

ENDO Online 2020

Virtual

June 8, 2020 – June 22, 2020

AACE 2020

Washington, DC

May 7, 2020 – May 10, 2020


Please see the full Prescribing Information for JATENZO, including BOXED WARNING on increases in blood pressure.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

JATENZO® is a registered trademark of Clarus Therapeutics, Inc.

Downward pointing arrow indicating download